title: Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men.
abstract: BACKGROUND
  Erectile dysfunction (ED) and cardiovascular disease share common risk factors and may be further aggravated by medical treatment for reducing them.
  
  
  OBJECTIVE
  The study was undertaken to assess the prevalence of ED in patients with diabetes (DM), hypertension (HTN), or both diseases, and to evaluate the effect of patient age, medical treatment, and disease duration and control on the prevalence of ED in this population.
  
  
  METHODS
  A group of 150 primary practitioners who had patients with known DM and/or HTN conducted a survey, utilizing IIEF-15, a 15-item multidimensional, self-administered questionnaire used for the clinical assessment of ED.
  
  
  RESULTS
  In all, 1,412 patients were included: 37% had DM, 38% had HTN, and 25% had both diseases. Their mean age was 55, 58, and 60 years, and 62, 46, and 67% had some degree of ED, respectively. The prevalence of ED increased with age and disease duration in each age group and was higher in subjects with DM than in those with HTN, especially in those aged < 65 years. Poor glycemic control was associated with a higher prevalence rate of ED early in the course of the disease. There was no significant difference in the prevalence of ED according to type and number of antihypertensive drugs.
  
  
  CONCLUSIONS
  Erectile dysfunction is common among patients at high risk for cardiovascular disease because of diabetes and/or HTN. Diabetic men are affected earlier than those with HTN. Given the high frequency of ED in young patients with these risk factors, physicians should encourage an open discussion on the subject during routine visits to promote early detection and treatment.
authors.affiliation: Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. arieroth@tasmc.health.gov.il
authors.forename: Arie
authors.initials: A
authors.lastname: Roth
authors.forename: Ofra
authors.initials: O
authors.lastname: Kalter-Leibovici
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Kerbis
authors.forename: Ella
authors.initials: E
authors.lastname: Tenenbaum-Koren
authors.forename: Juza
authors.initials: J
authors.lastname: Chen
authors.forename: Tamar
authors.initials: T
authors.lastname: Sobol
authors.forename: Itamar
authors.initials: I
authors.lastname: Raz
mesh_terms: D000367:Age Factors; D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D007172:Erectile Dysfunction / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007557:Israel / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D015995:Prevalence; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors